EC OK's Merck's Keytruda in first-line lung cancer

|About: Celgene Corporation (CELG)|By:, SA News Editor

As expected, the European Commision approves Merck's (NYSE:MRK) Keytruda (pembrolizumab), combined with carboplatin and Celgene's (NASDAQ:CELG) Abraxane (paclitaxel protein-bound), for the first-line treatment of adult patients with metastatic squamous non-small cell lung cancer (NSCLC).

In early February, the advisory group CHMP adopted a positive opinion backing approval.

Subscribe for full text news in your inbox